We are always introducing new clinical trials across our international network. If you can’t find what you are looking for please don’t hesitate to speak to your doctor to learn more, or contact us here.
Find a trial
At Icon, we offer clinical trials across various tumour types and blood disorders, allowing patients access to new and emerging advances in treatment, find a trial that might be suitable for you.
Use the search function below to find a clinical trial that may suit you and your cancer diagnosis
LOXO-FRA-24001 / J5E-OX-JZXA
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BGB-A317-26808-101
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BGB-24714-101
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
LOXO-ENC-23001 / J5A-OX-JZWA
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
DM005001
A Phase 1, Multicenter, Open-label, First-in-human, Dose Escalation and Expansion Study of DM005 in Patients With Advanced Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
VVD-130850-01
A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ARC-20
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
MTX-GPC3-303
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
LUNA / CP-MGC026-01
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors
Locations
Adelaide (Kurralta Park), Wesley
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
AWT020-001
A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
IL Believe
A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Locations
Farrer Park
Diagnosis
Advanced solid tumours, Cervical cancer, Lung cancer, Skin cancer – melanoma
Open for recruitment
View Trial
BBI-TP-3654-102
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
Locations
Adelaide (Windsor Gardens)
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
DB-1303-O-1001
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BGB-A317-A3055-101
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
AK127-101
A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
STARSTRUCK / 177Lu-TLX250-001
A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and peposertib in Patients with Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
HMDB-001-002
A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 Mutations
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ZN-c3-004
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma
Locations
Chermside
Diagnosis
Endometrial cancer
Trial on hold
View Trial
ZN-c3-005
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI)
Locations
Chermside
Diagnosis
Ovarian cancer
Trial on hold
View Trial
BA3011-002
A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1, EGFR, or ALK Inhibitor
Locations
Central Building (Oncology)
Diagnosis
Lung cancer
Open for recruitment
View Trial
ASPEN-06 / AT148006
A Phase 2/3 Study of ALX148 in Patients with Advanced HER2- Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Locations
Southport
Diagnosis
Gastric / gastroesophageal cancer
Open for recruitment
View Trial
REFRaME-01 / STRO-002-GM3
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Locations
Wesley
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
OLYMPIA-3 / R1979-ONC-2105
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (O-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
Locations
Wesley
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
View Trial
OLYMPIA-1 / R1979-HM-2298
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator’s Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)
Locations
Wesley
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
View Trial
Viktoria-1
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
View Trial
X4P-001-110
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Locations
Southport
Open for recruitment
View Trial
DeLLphi-306
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Locations
Mount Alvernia
Diagnosis
Lung cancer
Open for recruitment
View Trial
RAMP 301 / VS-6766-301
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator’s Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
Locations
Wesley
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
XPORT-EC-042
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Locations
Southport
Diagnosis
Endometrial cancer
Open for recruitment
View Trial
DM001001
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
SCTB14-X101
A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB14 in Patients With Advanced Malignant Solid Tumours
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
HX044-I-01
A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients With Advanced Solid Tumor Malignancies
Locations
Wesley
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BNT327-02
A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer
Locations
Wesley
Diagnosis
Breast cancer
Open for recruitment
View Trial
pionERA Breast Cancer
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
Locations
Gleneagles, Farrer Park
Diagnosis
Breast cancer
Open for recruitment
View Trial
pionERA
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
Locations
Gleneagles, Farrer Park
Diagnosis
Breast cancer
Open for recruitment
View Trial
INAVO122
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
View Trial
CAMBRIA-1
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
View Trial
SB221
A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients with Platinum-Resistant Ovarian Cancer
Locations
Adelaide (Kurralta Park)
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
EXPERT / ANZ1601
A Randomised Phase III Trial of Adjuvant Radiation Therapy Versus Observation Following Breast Conserving Surgery and Endocrine Therapy in Patients With Molecularly Characterised Luminal A Early Breast Cancer
Locations
Epworth Richmond
Diagnosis
Breast cancer
Open for recruitment
View Trial
I-MAT / MASC 03.18
A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma
Locations
Hobart
Diagnosis
Skin cancer – non-melanoma
Open for recruitment
View Trial
Duravelo-2 / BT8009-230
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Locations
Wesley
Diagnosis
Urothelial cancer
Open for recruitment
View Trial
STELLAR 303
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Locations
Farrer Park
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
STELLAR-304 / XL094-304
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Locations
Chermside
Diagnosis
Cancer-unknown origin
Open for recruitment
View Trial
EvoPAR-Prostate01 / D9723C00001
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Locations
Townsville, Chermside, Adelaide (Kurralta Park)
Diagnosis
Prostate cancer
Open for recruitment
View Trial
HLX10-020-SCLC302
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of Serplulimab or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Locations
Wesley
Diagnosis
Lung cancer
Open for recruitment
View Trial
ASPIRE / CL-SBP-101-04
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Locations
Adelaide (Kurralta Park)
Diagnosis
Pancreatic cancer
Trial on hold
View Trial
Relativity-106
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106)
Locations
Farrer Park
Diagnosis
Liver cancer
Open for recruitment
View Trial
C4391022
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Locations
Townsville
Diagnosis
Breast cancer
Open for recruitment
View Trial
AMLM22/D1
AMLM22/D1: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission
Locations
South Brisbane, Wesley, Chermside, Southport
Diagnosis
Leukaemia
Open for recruitment
View Trial
REGENERON_ R1979-ONC-1625
An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory B-cell non-hodgkin lymphoma
Locations
Farrer Park
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
View Trial
BGB-3111-LTE1
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies
Locations
Wesley
Diagnosis
B-cell malignancies
Open for recruitment
View Trial
SGNDV-001
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)
Locations
Chermside
Diagnosis
Urothelial cancer
Open for recruitment
View Trial
LINKER-MM3 / R5458-ONC-2245
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
Locations
Wesley
Diagnosis
Multiple myeloma
Open for recruitment
View Trial
CLINCH / ATG-022-ST-001
An Open, Multi-center, Phase I Clinical Study of ATG-022 in Patients with Advanced/metastatic Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ALLG NBCR
Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry
Locations
Wesley
Diagnosis
Leukaemia
Open for recruitment
View Trial
CAPTURE / BCT1901
BCT 1901 (CAPTURE): Women or men with oestrogen receptor positive, HER2 negative advanced breast cancer and PIK3CA mutant circulating DNA will be randomised to evaluate treatment with alpelisib plus fulvestrant compared with capecitabine on progression free survival.
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
BRIGHTLINE-2 / 1403-0011
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
LIBERATE
Clinical registry of focal low dose rate brachytherapy in men with biopsy confirmed low-intermediate risk prostate cancer (LIBERATE)
Locations
Epworth Richmond, Epworth Freemasons, Geelong
Diagnosis
Prostate cancer
Open for recruitment
View Trial
DECREASE / TROG 19.06
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Locations
Epworth Richmond
Diagnosis
Prostate cancer
Open for recruitment
View Trial
ERUPT
ERUPT Trial: Urethral scarring after radiation treatment for prostate cancer
Locations
Toowoomba
Diagnosis
Prostate cancer
Open for recruitment
View Trial
AMT-116-01
First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
AMT-151-01
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
AMT-253-01
First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
HERTHENA-PanTumor01 / U31402-277
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
Locations
Chermside, Hobart
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
Lunar-2
LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Locations
Farrer Park, Mount Alvernia
Diagnosis
Lung cancer
Open for recruitment
View Trial
MASTERPLAN
MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX and Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer with High Risk and Locally Advanced Disease
Locations
Gold Coast University Hospital
Diagnosis
Pancreatic cancer
Open for recruitment
View Trial
MRDR
Myeloma and Related Disease Registry
Locations
Wesley, Adelaide (Kurralta Park)
Diagnosis
Multiple myeloma
Open for recruitment
View Trial
OPTIMA / BCT 2202
Optimal personalised treatment of early breast cancer using multiparameter analysis
Locations
Southport, Wesley, Hobart, Adelaide (Kurralta Park), Adelaide (Windsor Gardens)
Diagnosis
Breast cancer
Open for recruitment
View Trial
SLN124-004
Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera
Locations
Adelaide (Kurralta Park)
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
HARMONY / R3767-ONC-2011
Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Locations
Hobart
Diagnosis
Skin cancer – melanoma
Open for recruitment
View Trial
VIKTORIA-1 / CELC-G-301
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy
Locations
Southport
Diagnosis
Breast cancer
Open for recruitment
View Trial
JSKN033-101
Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and efficacy of JSKN033 in Patients with Advanced or Metastatic Solid Malignant Tumours
Locations
Wesley
Diagnosis
Advanced solid tumours
Trial on hold
View Trial
ANZadapt / ANZUP 2101
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt)
Locations
Adelaide (Kurralta Park), Adelaide (Windsor Gardens)
Diagnosis
Prostate cancer
Open for recruitment
View Trial
PRIME_LUNG
PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer. A Pilot Study
Locations
Gold Coast University Hospital
Diagnosis
Lung cancer
Open for recruitment
View Trial
FIG / TROG 18.06
Prospective, multicentre trial evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography in Glioblastoma (FET-PET in Glioblastoma)
Locations
Wesley
Diagnosis
Brain cancer
Open for recruitment
View Trial
TREMOR
Safety and effectiveness of frameless linac-based stereotactic radiosurgery on tremor in patients with essential tremor or Parkinson’s disease (TREMOR study)
Locations
Epworth Richmond
Diagnosis
Neurological conditions
Open for recruitment
View Trial
KEYVIBE-006 / MK-7684A-006
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer
Locations
Hobart
Diagnosis
Lung cancer
Open for recruitment
View Trial
SUNRAY-01 / J3M-MC-JZQB
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Locations
Wesley
Diagnosis
Lung cancer
Open for recruitment
View Trial
Q-IMPROvE
The Q-IMPROvE (Queensland-IMplementation of PRecision Oncology in brEast cancer) pilot study
Locations
Wesley
Diagnosis
Breast cancer
Open for recruitment
View Trial
ROSEND
The ROSEND Trial – A Randomised trial for the treatment of recalcitrant symptomatic rosacea using definitive volumetric modulated arc radiotherapy or standard dermatological treatment
Locations
Revesby, Gosford
Diagnosis
Skin cancer – non-melanoma
Open for recruitment
View Trial
BGB-A317-LBL-007-201
This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine to participants with colorectal cancer
Locations
South Brisbane
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
ABCPro
Trial is evaluating a new online service for managing self-reported symptoms by people with advanced breast cancer.
Locations
Bowen Icon Cancer Centre
Diagnosis
Breast cancer
Open for recruitment
View Trial
TRACIE / CO-AU-979-6695
TRodelvy use in AdvanCed TrIple Negative BrEast Cancer in Australia
Locations
Adelaide (Kurralta Park), Adelaide (Windsor Gardens), Townsville, Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
TUGETHER / BCT2102
Tucatinib together with Pembrolizumab and Trastuzumab: A Phase II, Two-Arm, Non-Comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab (MK-3475) and Trastuzumab in Patients with Pre-Treated Advanced HER2-Positive Breast Cancer
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
There are no clinical trials currently available
Become a patient
Find out how to become a patient at Icon Cancer Centre, or request more information from your nearest centre.
Download your free Cancer Diagnosis Checklist
Be more informed and have an active role in your care; download 'Questions to Ask Your Doctor After Cancer Diagnosis'.
Care at Icon
At Icon, care is more than just a word. Our cancer care team are here to support you with compassion, knowledge and hope.
Iconic Community
Our patients share their perspective and advice.